Article Clinical Trials Data Tincture 
Cannabis Law Report
MAY 10, 2022
First academic study of national medicinal cannabis data. This is despite a limited number of high-quality clinical trials investigating the drug’s efficacy for this condition. The authors note, however, that the data doesn’t include patient outcomes. Here’s the Uni of Sydney press release. 11 May 2022.
Project CBD
FEBRUARY 28, 2023
HerbalGram, the acclaimed quarterly journal of the American Botanical Council, recently published its 2021 “Herb Market Report,” which included data on sales of CBD as an herbal ingredient in mainstream and natural retail channels in the United States. Available at: www.ncbi.nlm.nih.gov/pmc/articles/PMC7400098/.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Freedom Leaf
JANUARY 10, 2018
“We’re actively working toward developing new genetics to work on efficacy and assist the patients in Israel still operating with our nurse-run clinics in order to better provide the right dosage and strains for the patients who are referred to us by the Ministry of Health,” Stephen Gardner, Tikun Olam’s chief marketing officer, tells Freedom Leaf.
The Joint Blog
FEBRUARY 24, 2021
Numerous trials have been run using medical marijuana and CBD tinctures to treat or reduce the symptoms of Parkinson’s Disease. This is not the first medicinal trial of its kind. The effects were so promising that Parkinson’s UK began funding for the worlds first clinical trial. This trial was to take 3.5
The Cannigma
JUNE 15, 2021
Cannabis products such as oils, tinctures and creams are usually decarboxylated as part of their preparation. However, the scientific data on CBG is nowhere near as developed as what we have on CBD. Indeed, the scientific literature regarding CBD and some forms of epilepsy is rich and full of data.
Cannabis Law Report
JULY 24, 2019
FDA has determined that your “CBD Lotion,” “CBD Pain-Relief Patch,” “CBD Tincture,” and “CBD Disposable Vape Pen” products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). Unapproved New and Misbranded Human Drug Products.
TheAnswerPage
JANUARY 11, 2022
As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).
Expert insights. Personalized for you.
52 
Let's personalize your content